We describe the initial results of Emicizumab prophylaxis in twins
diagnosed with severe Hemophilia A and inhibitors with intron 22
inversion. Prophylaxis was initiated in both the twins showing high
annual bleed rate and difficult venous access. The treatment resulted in
zero spontaneous bleeds and there were no adverse events.